Details of the Drug Combination

General Information of Drug Combination (ID: DCHR70S)

Drug Combination Name
Clopidogrel Vinblastine
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Clopidogrel   DMOL54H Vinblastine   DM5TVS3
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 3.01
Bliss Independence Score: 3.01
Loewe Additivity Score: 3.54
LHighest Single Agent (HSA) Score: 3.57

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Clopidogrel
Disease Entry ICD 11 Status REF
Acute coronary syndrome BA41 Approved [2]
Atherosclerosis BD40 Approved [2]
Myocardial infarction BA41-BA43 Approved [2]
Thrombosis DB61-GB90 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [4]
Intracranial embolism 8B22.1 Investigative [2]
Clopidogrel Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
P2Y purinoceptor 12 (P2RY12) TTZ1DT0 P2Y12_HUMAN Antagonist [7]
------------------------------------------------------------------------------------
Clopidogrel Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]
------------------------------------------------------------------------------------
Clopidogrel Interacts with 6 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [9]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [10]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [11]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [11]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Metabolism [12]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [13]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DME(s)
Clopidogrel Interacts with 26 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [14]
Cytochrome P450 2B6 (CYP2B6) OTOYO4S7 CP2B6_HUMAN Increases Expression [14]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Increases Oxidation [15]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Affects Response To Substance [16]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Decreases Expression [8]
P2Y purinoceptor 12 (P2RY12) OTX2W0WD P2Y12_HUMAN Affects Response To Substance [17]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Increases ADR [18]
Stearoyl-CoA desaturase (SCD) OTB1073G SCD_HUMAN Decreases Expression [14]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [19]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Decreases Activity [20]
Thrombospondin-1 (THBS1) OT0ECWK3 TSP1_HUMAN Increases Expression [19]
C-C motif chemokine 4 (CCL4) OT6B8P25 CCL4_HUMAN Increases Expression [21]
C-C motif chemokine 5 (CCL5) OTSCA5CK CCL5_HUMAN Increases Expression [21]
Brain-derived neurotrophic factor (BDNF) OTLGH7EW BDNF_HUMAN Decreases Secretion [22]
Phosphoenolpyruvate carboxykinase, cytosolic (PCK1) OTNWEJ5Y PCKGC_HUMAN Increases Expression [14]
Glucose-6-phosphatase catalytic subunit 1 (G6PC1) OTJ6FM9F G6PC1_HUMAN Decreases Expression [14]
Tight junction protein ZO-1 (TJP1) OTBDCUPK ZO1_HUMAN Decreases Expression [23]
Nuclear receptor subfamily 1 group I member 3 (NR1I3) OTS3SGH7 NR1I3_HUMAN Affects Localization [14]
Occludin (OCLN) OTSUTVWL OCLN_HUMAN Decreases Expression [23]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Activity [20]
Thyroid hormone-inducible hepatic protein (THRSP) OTKYE01L THRSP_HUMAN Increases Expression [14]
Proteinase-activated receptor 1 (F2R) OT4WVWBO PAR1_HUMAN Affects Response To Substance [24]
Serum paraoxonase/arylesterase 1 (PON1) OTD0Z2XO PON1_HUMAN Affects Response To Substance [25]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Decreases Metabolism [26]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Increases Response To Substance [27]
Integrin beta-3 (ITGB3) OTWCK1K6 ITB3_HUMAN Decreases Response To Substance [28]
------------------------------------------------------------------------------------
⏷ Show the Full List of 26 DOT(s)
Indication(s) of Vinblastine
Disease Entry ICD 11 Status REF
Advanced cancer 2A00-2F9Z Approved [5]
Anterior urethra cancer N.A. Approved [5]
Extragonadal germ cell tumor N.A. Approved [5]
Gestational trophoblastic neoplasia 2F33-2F76 Approved [5]
Kaposi sarcoma 2B57 Approved [5]
Mycosis fungoides 2B01 Approved [5]
Posterior urethra cancer N.A. Approved [5]
Solid tumour/cancer 2A00-2F9Z Approved [6]
Testicular cancer 2C80 Approved [5]
Testicular germ cell tumor N.A. Approved [5]
Classic Hodgkin lymphoma N.A. Investigative [5]
Vinblastine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tubulin beta-2 chain (TUBB2) TTJ2PTI TBB2A_HUMAN Inhibitor [30]
------------------------------------------------------------------------------------
Vinblastine Interacts with 5 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [31]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [32]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [33]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [34]
Multidrug resistance protein 3 (ABCB4) DTZRMK5 MDR3_HUMAN Substrate [35]
------------------------------------------------------------------------------------
Vinblastine Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [36]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [37]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [38]
------------------------------------------------------------------------------------
Vinblastine Interacts with 201 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Decreases Response To Substance [39]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Decreases Response To Substance [40]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Affects Transport [41]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [42]
Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB) OT9RDS3H IKKB_HUMAN Increases Phosphorylation [43]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Activity [44]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Increases Expression [45]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Increases Stability [46]
Intercellular adhesion molecule 1 (ICAM1) OTTOIX77 ICAM1_HUMAN Decreases Expression [47]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Phosphorylation [48]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Stability [46]
Integrin alpha-L (ITGAL) OTCUQAIS ITAL_HUMAN Decreases Expression [47]
NF-kappa-B inhibitor alpha (NFKBIA) OTFT924M IKBA_HUMAN Increases Phosphorylation [43]
Mitogen-activated protein kinase 8 (MAPK8) OTEREYS5 MK08_HUMAN Increases Phosphorylation [48]
Mitogen-activated protein kinase 9 (MAPK9) OTCEVJ9E MK09_HUMAN Increases Phosphorylation [48]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Increases Expression [49]
Protein kinase C delta type (PRKCD) OTSEH90E KPCD_HUMAN Affects Localization [45]
Nuclear factor of activated T-cells, cytoplasmic 4 (NFATC4) OTTDCUAO NFAC4_HUMAN Decreases Localization [50]
Transcriptional regulator QRICH1 (QRICH1) OTPVAX04 QRIC1_HUMAN Increases Phosphorylation [51]
Sorting nexin-10 (SNX10) OT05B7BT SNX10_HUMAN Affects Response To Substance [29]
Histone H1.2 (H1-2) OT0AVI4M H12_HUMAN Affects Response To Substance [29]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Affects Response To Substance [29]
Friend leukemia integration 1 transcription factor (FLI1) OT0EV3LX FLI1_HUMAN Affects Response To Substance [29]
Sulfotransferase 1A1 (SULT1A1) OT0K7JIE ST1A1_HUMAN Affects Response To Substance [29]
Histone H3-like centromeric protein A (CENPA) OT0NEJ4X CENPA_HUMAN Affects Response To Substance [29]
DNA polymerase zeta catalytic subunit (REV3L) OT0OP8EJ REV3L_HUMAN Affects Response To Substance [29]
Rab11 family-interacting protein 1 (RAB11FIP1) OT0T71OW RFIP1_HUMAN Affects Response To Substance [29]
Oxysterol-binding protein-related protein 10 (OSBPL10) OT0TFMBE OSB10_HUMAN Affects Response To Substance [29]
DNA-binding protein inhibitor ID-2 (ID2) OT0U1D53 ID2_HUMAN Affects Response To Substance [29]
NADH dehydrogenase 1 alpha subcomplex subunit 13 (NDUFA13) OT0UOKIT NDUAD_HUMAN Affects Response To Substance [29]
Tripartite motif-containing protein 2 (TRIM2) OT0V1YVC TRIM2_HUMAN Affects Response To Substance [29]
Lamin-B1 (LMNB1) OT100T3P LMNB1_HUMAN Affects Response To Substance [29]
Borealin (CDCA8) OT17D55D BOREA_HUMAN Affects Response To Substance [29]
G2/mitotic-specific cyclin-B1 (CCNB1) OT19S7E5 CCNB1_HUMAN Increases Response To Substance [52]
Condensin complex subunit 3 (NCAPG) OT1AI9EO CND3_HUMAN Affects Response To Substance [29]
m7GpppX diphosphatase (DCPS) OT1FZVC9 DCPS_HUMAN Affects Response To Substance [29]
KN motif and ankyrin repeat domain-containing protein 1 (KANK1) OT2E7A6W KANK1_HUMAN Affects Response To Substance [29]
Aldehyde oxidase (AOX1) OT2FZP6H AOXA_HUMAN Affects Response To Substance [29]
U11/U12 small nuclear ribonucleoprotein 25 kDa protein (SNRNP25) OT2MR6O2 SNR25_HUMAN Affects Response To Substance [29]
Pyruvate dehydrogenase E1 component subunit beta, mitochondrial (PDHB) OT2NHE5E ODPB_HUMAN Affects Response To Substance [29]
N-acetylglucosamine-1-phosphotransferase subunits alpha/beta (GNPTAB) OT2Z03OB GNPTA_HUMAN Affects Response To Substance [29]
Superoxide dismutase (SOD1) OT39TA1L SODC_HUMAN Affects Response To Substance [29]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Affects Response To Substance [29]
Chromosome-associated kinesin KIF4A (KIF4A) OT3UWL7D KIF4A_HUMAN Affects Response To Substance [29]
NADH dehydrogenase 1 beta subcomplex subunit 2, mitochondrial (NDUFB2) OT4717TF NDUB2_HUMAN Affects Response To Substance [29]
High mobility group protein B1 (HMGB1) OT4B7CPF HMGB1_HUMAN Affects Response To Substance [29]
c-Myc-binding protein (MYCBP) OT4IZR4R MYCBP_HUMAN Affects Response To Substance [29]
Hyaluronan mediated motility receptor (HMMR) OT4M0JTZ HMMR_HUMAN Affects Response To Substance [29]
Transcription termination factor 2 (TTF2) OT5LJOWM TTF2_HUMAN Affects Response To Substance [29]
Neprilysin (MME) OT5Q39P8 NEP_HUMAN Affects Response To Substance [29]
Peptidyl-prolyl cis-trans isomerase FKBP1A (FKBP1A) OT6285L4 FKB1A_HUMAN Affects Response To Substance [29]
DNA topoisomerase 2-alpha (TOP2A) OT6LPS08 TOP2A_HUMAN Affects Response To Substance [29]
Electron transfer flavoprotein subunit beta (ETFB) OT6Q6FBD ETFB_HUMAN Affects Response To Substance [29]
Flap endonuclease 1 (FEN1) OT6QGG7O FEN1_HUMAN Affects Response To Substance [29]
G-protein-signaling modulator 2 (GPSM2) OT6RPMRM GPSM2_HUMAN Affects Response To Substance [29]
Plasminogen activator inhibitor 2 (SERPINB2) OT72QLZB PAI2_HUMAN Affects Response To Substance [29]
CD40 ligand (CD40LG) OT75Z6A6 CD40L_HUMAN Decreases Response To Substance [53]
Mitotic checkpoint serine/threonine-protein kinase BUB1 (BUB1) OT80DZMT BUB1_HUMAN Affects Response To Substance [29]
Nucleolar and spindle-associated protein 1 (NUSAP1) OT85HIJ5 NUSAP_HUMAN Affects Response To Substance [29]
Stanniocalcin-2 (STC2) OT86YP8G STC2_HUMAN Affects Response To Substance [29]
Pirin (PIR) OT8ALXHU PIR_HUMAN Affects Response To Substance [29]
NADH dehydrogenase 1 alpha subcomplex subunit 7 (NDUFA7) OT8CV3H5 NDUA7_HUMAN Affects Response To Substance [29]
G0/G1 switch protein 2 (G0S2) OT8FL49L G0S2_HUMAN Affects Response To Substance [29]
Replication protein A 14 kDa subunit (RPA3) OT8JAQGL RFA3_HUMAN Affects Response To Substance [29]
Deoxyribose-phosphate aldolase (DERA) OT8SMO3N DEOC_HUMAN Affects Response To Substance [29]
NADH dehydrogenase iron-sulfur protein 6, mitochondrial (NDUFS6) OT9IOONQ NDUS6_HUMAN Affects Response To Substance [29]
NADH dehydrogenase 1 subunit C2 (NDUFC2) OT9M119L NDUC2_HUMAN Affects Response To Substance [29]
Beta-glucuronidase (GUSB) OT9N1DK3 BGLR_HUMAN Affects Response To Substance [29]
Fos-related antigen 1 (FOSL1) OT9YTYMB FOSL1_HUMAN Affects Response To Substance [29]
High mobility group nucleosome-binding domain-containing protein 3 (HMGN3) OTA2TBWS HMGN3_HUMAN Affects Response To Substance [29]
Diphosphoinositol polyphosphate phosphohydrolase NUDT4B (NUDT4) OTA6ICI2 NUD4B_HUMAN Affects Response To Substance [29]
Cysteine-rich PDZ-binding protein (CRIPT) OTA6M8M4 CRIPT_HUMAN Affects Response To Substance [29]
Replication factor C subunit 5 (RFC5) OTAD79RT RFC5_HUMAN Affects Response To Substance [29]
ATP synthase subunit e, mitochondrial (ATP5ME) OTADVEE2 ATP5I_HUMAN Affects Response To Substance [29]
Transmembrane protein 14A (TMEM14A) OTANQA6G TM14A_HUMAN Affects Response To Substance [29]
MAP kinase-activated protein kinase 5 (MAPKAPK5) OTAZHPVK MAPK5_HUMAN Affects Response To Substance [29]
Shootin-1 (SHTN1) OTB07MOG SHOT1_HUMAN Affects Response To Substance [29]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Affects Response To Substance [29]
Fibronectin (FN1) OTB5ZN4Q FINC_HUMAN Affects Response To Substance [29]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) OTB97VIK IF2B3_HUMAN Affects Response To Substance [29]
Membrane-associated progesterone receptor component 1 (PGRMC1) OTBE6WAC PGRC1_HUMAN Affects Response To Substance [29]
Probable ATP-dependent RNA helicase DDX23 (DDX23) OTBJHS8C DDX23_HUMAN Affects Response To Substance [29]
Protein FAM3C (FAM3C) OTBR6U9G FAM3C_HUMAN Affects Response To Substance [29]
Transmembrane protein 134 (TMEM134) OTBX9H9D TM134_HUMAN Affects Response To Substance [29]
Dual specificity protein kinase TTK (TTK) OTBY1Z5H TTK_HUMAN Affects Response To Substance [29]
CCN family member 2 (CCN2) OTC39NSU CCN2_HUMAN Affects Response To Substance [29]
Cyclin-dependent kinase 4 inhibitor C (CDKN2C) OTCLOV90 CDN2C_HUMAN Affects Response To Substance [29]
Cytoskeleton-associated protein 2 (CKAP2) OTCLTC0J CKAP2_HUMAN Affects Response To Substance [29]
Cytochrome c oxidase copper chaperone (COX17) OTCP4LH2 COX17_HUMAN Affects Response To Substance [29]
Tetraspanin-13 (TSPAN13) OTCS9BZY TSN13_HUMAN Affects Response To Substance [29]
S-phase kinase-associated protein 2 (SKP2) OTD5B41X SKP2_HUMAN Affects Response To Substance [29]
Succinate--CoA ligase subunit alpha, mitochondrial (SUCLG1) OTDCSPXH SUCA_HUMAN Affects Response To Substance [29]
Proteasome activator complex subunit 4 (PSME4) OTDGF53O PSME4_HUMAN Affects Response To Substance [29]
Gamma-adducin (ADD3) OTDRSHAZ ADDG_HUMAN Affects Response To Substance [29]
Superkiller complex protein 8 (SKIC8) OTDSQYDN SKI8_HUMAN Affects Response To Substance [29]
Dickkopf-related protein 3 (DKK3) OTDU94EY DKK3_HUMAN Affects Response To Substance [29]
Geminin (GMNN) OTDYKNIY GEMI_HUMAN Affects Response To Substance [29]
EF-hand calcium-binding domain-containing protein 7 (EFCAB7) OTE0EG10 EFCB7_HUMAN Affects Response To Substance [29]
Vitamin K-dependent gamma-carboxylase (GGCX) OTE0FNAP VKGC_HUMAN Affects Response To Substance [29]
ATP synthase subunit f, mitochondrial (ATP5MF) OTE4TBG9 ATPK_HUMAN Affects Response To Substance [29]
Maternal embryonic leucine zipper kinase (MELK) OTEY2UQA MELK_HUMAN Affects Response To Substance [29]
Protein pelota homolog (PELO) OTF3WLIM PELO_HUMAN Affects Response To Substance [29]
Serglycin (SRGN) OTFAVSX0 SRGN_HUMAN Affects Response To Substance [29]
Sortilin (SORT1) OTFCQ4B1 SORT_HUMAN Affects Response To Substance [29]
Exosome complex component RRP45 (EXOSC9) OTFKB37F EXOS9_HUMAN Affects Response To Substance [29]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Affects Response To Substance [29]
High mobility group protein B2 (HMGB2) OTGEGAOK HMGB2_HUMAN Affects Response To Substance [29]
Phospholipid-transporting ATPase ABCA3 (ABCA3) OTH6MSKQ ABCA3_HUMAN Decreases Response To Substance [54]
Sigma intracellular receptor 2 (TMEM97) OTH76ZWK SGMR2_HUMAN Affects Response To Substance [29]
Transmembrane protein 156 (TMEM156) OTH7YJID TM156_HUMAN Affects Response To Substance [29]
Epithelial cell adhesion molecule (EPCAM) OTHBZK5X EPCAM_HUMAN Affects Response To Substance [29]
Protein regulator of cytokinesis 1 (PRC1) OTHD0XS0 PRC1_HUMAN Affects Response To Substance [29]
Catalase (CAT) OTHEBX9R CATA_HUMAN Affects Response To Substance [29]
Kinesin-like protein KIF11 (KIF11) OTHRGLCQ KIF11_HUMAN Affects Response To Substance [29]
Actin-binding LIM protein 1 (ABLIM1) OTHXEK3E ABLM1_HUMAN Affects Response To Substance [29]
U6 snRNA-associated Sm-like protein LSm7 (LSM7) OTHZ2XPX LSM7_HUMAN Affects Response To Substance [29]
Kinesin-like protein KIF1B (KIF1B) OTI1XQTO KIF1B_HUMAN Affects Response To Substance [29]
Interstitial collagenase (MMP1) OTI4I2V1 MMP1_HUMAN Affects Response To Substance [29]
Protein Mis18-beta (OIP5) OTI5C2DE MS18B_HUMAN Affects Response To Substance [29]
G2/mitotic-specific cyclin-B2 (CCNB2) OTIEXTDK CCNB2_HUMAN Affects Response To Substance [29]
Securin (PTTG1) OTIMYS4W PTTG1_HUMAN Affects Response To Substance [29]
Baculoviral IAP repeat-containing protein 7 (BIRC7) OTITCGHB BIRC7_HUMAN Decreases Response To Substance [55]
Aurora kinase B (AURKB) OTIY4VHU AURKB_HUMAN Affects Response To Substance [29]
NADH dehydrogenase 1 subunit C1, mitochondrial (NDUFC1) OTJ5TNHB NDUC1_HUMAN Affects Response To Substance [29]
Low molecular weight phosphotyrosine protein phosphatase (ACP1) OTJ9CKLU PPAC_HUMAN Affects Response To Substance [29]
G/T mismatch-specific thymine DNA glycosylase (TDG) OTJB0YIH TDG_HUMAN Affects Response To Substance [29]
E3 ubiquitin-protein ligase FANCL (FANCL) OTJC7QPQ FANCL_HUMAN Affects Response To Substance [29]
Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial (HADH) OTJDOL20 HCDH_HUMAN Affects Response To Substance [29]
Lysophosphatidic acid receptor 1 (LPAR1) OTJNJQPF LPAR1_HUMAN Affects Response To Substance [29]
Kinesin-like protein KIF15 (KIF15) OTJRJEXL KIF15_HUMAN Affects Response To Substance [29]
TBC1 domain family member 4 (TBC1D4) OTK66C40 TBCD4_HUMAN Affects Response To Substance [29]
Tyrosine-protein kinase receptor UFO (AXL) OTKA2SUX UFO_HUMAN Affects Response To Substance [29]
Gamma-glutamylcyclotransferase (GGCT) OTKAICP5 GGCT_HUMAN Affects Response To Substance [29]
NADH dehydrogenase 1 alpha subcomplex subunit 1 (NDUFA1) OTKBUQXP NDUA1_HUMAN Affects Response To Substance [29]
Origin recognition complex subunit 6 (ORC6) OTKQN3KP ORC6_HUMAN Affects Response To Substance [29]
Sideroflexin-1 (SFXN1) OTL66767 SFXN1_HUMAN Affects Response To Substance [29]
Lamina-associated polypeptide 2, isoform alpha (TMPO) OTL68EL4 LAP2A_HUMAN Affects Response To Substance [29]
Transcription factor E2F1 (E2F1) OTLKYBBC E2F1_HUMAN Increases Response To Substance [52]
Striatin (STRN) OTLOZL5I STRN_HUMAN Affects Response To Substance [29]
Succinate--CoA ligase subunit beta, mitochondrial (SUCLA2) OTMZD4PW SUCB1_HUMAN Affects Response To Substance [29]
Protein downstream neighbor of Son (DONSON) OTN5HE0W DONS_HUMAN Affects Response To Substance [29]
Cytochrome c oxidase subunit 6B1 (COX6B1) OTNKXYQI CX6B1_HUMAN Affects Response To Substance [29]
Keratinocyte-associated transmembrane protein 2 (C5ORF15) OTO126A1 KCT2_HUMAN Affects Response To Substance [29]
Receptor tyrosine-protein kinase erbB-2 (ERBB2) OTOAUNCK ERBB2_HUMAN Affects Response To Substance [56]
tRNA (TRMT5) OTOAZBPD TRM5_HUMAN Affects Response To Substance [29]
Ribonucleoside-diphosphate reductase subunit M2 (RRM2) OTOB6J6R RIR2_HUMAN Affects Response To Substance [29]
Cytochrome c oxidase subunit 5A, mitochondrial (COX5A) OTP0961M COX5A_HUMAN Affects Response To Substance [29]
DNA fragmentation factor subunit beta (DFFB) OTPBW5N5 DFFB_HUMAN Affects Response To Substance [29]
Interleukin-13 receptor subunit alpha-2 (IL13RA2) OTPC2G0X I13R2_HUMAN Affects Response To Substance [29]
DNA dC->dU-editing enzyme APOBEC-3C (APOBEC3C) OTPL0AI1 ABC3C_HUMAN Affects Response To Substance [29]
Kazrin (KAZN) OTPM7BYM KAZRN_HUMAN Affects Response To Substance [29]
G2 and S phase-expressed protein 1 (GTSE1) OTPP742Z GTSE1_HUMAN Affects Response To Substance [29]
Prostaglandin E synthase 3 (PTGES3) OTPPQWI0 TEBP_HUMAN Affects Response To Substance [29]
Epithelial membrane protein 2 (EMP2) OTPS2H0L EMP2_HUMAN Affects Response To Substance [29]
Ornithine decarboxylase antizyme 1 (OAZ1) OTPT0PKZ OAZ1_HUMAN Affects Response To Substance [29]
Sister chromatid cohesion protein DCC1 (DSCC1) OTPUVLZT DCC1_HUMAN Affects Response To Substance [29]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Affects Response To Substance [57]
Pentraxin-related protein PTX3 (PTX3) OTPXHRKU PTX3_HUMAN Affects Response To Substance [29]
Ran-specific GTPase-activating protein (RANBP1) OTQE226K RANG_HUMAN Affects Response To Substance [29]
Rac GTPase-activating protein 1 (RACGAP1) OTQE8IEH RGAP1_HUMAN Affects Response To Substance [29]
MAPK/MAK/MRK overlapping kinase (MOK) OTQK7M9V MOK_HUMAN Affects Response To Substance [29]
3-oxo-5-alpha-steroid 4-dehydrogenase 1 (SRD5A1) OTQRET2B S5A1_HUMAN Affects Response To Substance [29]
Solute carrier family 22 member 3 (SLC22A3) OTQYGVXX S22A3_HUMAN Affects Response To Substance [29]
Large ribosomal subunit protein mL63 (MRPL57) OTRB659E RT63_HUMAN Affects Response To Substance [29]
Dickkopf-related protein 1 (DKK1) OTRDLUSP DKK1_HUMAN Affects Response To Substance [29]
Olfactory receptor 1I1 (OR1I1) OTRFD8BH OR1I1_HUMAN Affects Response To Substance [29]
Protein CREG1 (CREG1) OTRHJ8HK CREG1_HUMAN Affects Response To Substance [29]
Proepiregulin (EREG) OTRM4NQY EREG_HUMAN Affects Response To Substance [29]
Kinetochore protein NDC80 homolog (NDC80) OTS7D306 NDC80_HUMAN Affects Response To Substance [29]
Latent-transforming growth factor beta-binding protein 2 (LTBP2) OTS88GSD LTBP2_HUMAN Affects Response To Substance [29]
Tumor protein D53 (TPD52L1) OTSA6U0I TPD53_HUMAN Affects Response To Substance [29]
Inhibin beta A chain (INHBA) OTSP64PQ INHBA_HUMAN Affects Response To Substance [29]
Leucine-rich repeat-containing protein 1 (LRRC1) OTSVD30Q LRRC1_HUMAN Affects Response To Substance [29]
NADH dehydrogenase flavoprotein 2, mitochondrial (NDUFV2) OTSZF7D6 NDUV2_HUMAN Affects Response To Substance [29]
Plasminogen activator inhibitor 1 (SERPINE1) OTT0MPQ3 PAI1_HUMAN Affects Response To Substance [29]
Rho GTPase-activating protein SYDE1 (SYDE1) OTTIAF4D SYDE1_HUMAN Affects Response To Substance [29]
Isocitrate dehydrogenase , mitochondrial (IDH2) OTTQA4PB IDHP_HUMAN Affects Response To Substance [29]
Importin subunit alpha-1 (KPNA2) OTU7FOE6 IMA1_HUMAN Affects Response To Substance [29]
General transcription factor II-I (GTF2I) OTUYL1TQ GTF2I_HUMAN Affects Response To Substance [29]
Integrin beta-1-binding protein 1 (ITGB1BP1) OTVQFNGS ITBP1_HUMAN Affects Response To Substance [29]
Transcription factor IIIA (GTF3A) OTVROUVQ TF3A_HUMAN Affects Response To Substance [29]
ATP-binding cassette sub-family A member 2 (ABCA2) OTVSYK0X ABCA2_HUMAN Decreases Response To Substance [54]
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Affects Response To Substance [29]
Serine/threonine-protein kinase 26 (STK26) OTW4QE0D STK26_HUMAN Affects Response To Substance [29]
Homer protein homolog 1 (HOMER1) OTWFD3SI HOME1_HUMAN Affects Response To Substance [29]
Acyl-coenzyme A thioesterase 13 (ACOT13) OTWRUST1 ACO13_HUMAN Affects Response To Substance [29]
Divergent protein kinase domain 1A (DIPK1A) OTWS5V2I DIK1A_HUMAN Affects Response To Substance [29]
Urokinase-type plasminogen activator (PLAU) OTX0QGKK UROK_HUMAN Affects Response To Substance [29]
Hematopoietic lineage cell-specific protein (HCLS1) OTX7WGYN HCLS1_HUMAN Affects Response To Substance [29]
Nucleotide triphosphate diphosphatase NUDT15 (NUDT15) OTX8SZOT NUD15_HUMAN Affects Response To Substance [29]
NADH dehydrogenase 1 alpha subcomplex subunit 3 (NDUFA3) OTXL10N9 NDUA3_HUMAN Affects Response To Substance [29]
Mitotic spindle assembly checkpoint protein MAD2A (MAD2L1) OTXNGZCG MD2L1_HUMAN Affects Response To Substance [29]
Kinesin-like protein KIF20A (KIF20A) OTXOQHE0 KI20A_HUMAN Affects Response To Substance [29]
Condensin complex subunit 2 (NCAPH) OTXOS97C CND2_HUMAN Affects Response To Substance [29]
Kinesin-like protein KIF23 (KIF23) OTY850JC KIF23_HUMAN Affects Response To Substance [29]
Protein FAN (NSMAF) OTYNVZ23 FAN_HUMAN Affects Response To Substance [29]
Proteasome subunit beta type-1 (PSMB1) OTYRFBAH PSB1_HUMAN Affects Response To Substance [29]
Acetyl-CoA acetyltransferase, cytosolic (ACAT2) OTZ092ZJ THIC_HUMAN Affects Response To Substance [29]
G-protein coupled receptor 176 (GPR176) OTZ8PL9B GP176_HUMAN Affects Response To Substance [29]
Tissue factor pathway inhibitor 2 (TFPI2) OTZCRWOR TFPI2_HUMAN Affects Response To Substance [29]
C-X-C motif chemokine 5 (CXCL5) OTZOUPCA CXCL5_HUMAN Affects Response To Substance [29]
------------------------------------------------------------------------------------
⏷ Show the Full List of 201 DOT(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Clopidogrel FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7150).
4 Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial. (C-19-ACS)
5 Vinblastine FDA Label
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6851).
7 P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003 May;3(2):113-22.
8 Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006 Nov;80(5):486-501.
9 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
10 Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet. 2015 Feb;54(2):147-66.
11 Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007 May;81(5):735-41.
12 Clopidogrel pathway. Pharmacogenet Genomics. 2010 Jul;20(7):463-5.
13 Impact of the CYP2C19 gene polymorphism on clopidogrel personalized drug regimen and the clinical outcomes. Clin Lab. 2016 Sep 1;62(9):1773-1780.
14 Identification of novel agonists by high-throughput screening and molecular modelling of human constitutive androstane receptor isoform 3. Arch Toxicol. 2019 Aug;93(8):2247-2264. doi: 10.1007/s00204-019-02495-6. Epub 2019 Jul 16.
15 Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010 Jan;38(1):92-9. doi: 10.1124/dmd.109.029132.
16 Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ. 2006 Jun 6;174(12):1715-22. doi: 10.1503/cmaj.060664.
17 Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene. Int J Cardiol. 2009 Apr 17;133(3):341-5. doi: 10.1016/j.ijcard.2007.12.118. Epub 2008 May 15.
18 Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22.
19 Angiogenesis inhibitor SR 25989 upregulates thrombospondin-1 expression in human vascular endothelial cells and foreskin fibroblasts. Biol Cell. 1997 Jul;89(4):295-307.
20 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
21 Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study. J Thromb Haemost. 2006 Oct;4(10):2140-7. doi: 10.1111/j.1538-7836.2006.02131.x. Epub 2006 Jul 17.
22 Differential effect of clopidogrel and aspirin on the release of BDNF from platelets. J Neuroimmunol. 2011 Sep 15;238(1-2):104-6. doi: 10.1016/j.jneuroim.2011.06.015. Epub 2011 Jul 31.
23 Attenuated expression of the tight junction proteins is involved in clopidogrel-induced gastric injury through p38 MAPK activation. Toxicology. 2013 Feb 8;304:41-8. doi: 10.1016/j.tox.2012.11.020. Epub 2012 Dec 7.
24 PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy. Platelets. 2005 Sep;16(6):340-5. doi: 10.1080/00207230500120294.
25 Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med. 2011 Jan;17(1):110-6. doi: 10.1038/nm.2281. Epub 2010 Dec 19.
26 Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007 Dec;5(12):2429-36. doi: 10.1111/j.1538-7836.2007.02775.x. Epub 2007 Sep 26.
27 Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2. Mol Pharmacol. 2007 Sep;72(3):686-94. doi: 10.1124/mol.107.036889. Epub 2007 May 30.
28 High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial. Blood Coagul Fibrinolysis. 2009 Jun;20(4):257-62. doi: 10.1097/mbc.0b013e328325455b.
29 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
30 Effect of the antitumor drug vinblastine on nuclear betaII-tubulin in cultured rat kidney mesangial cells. Invest New Drugs. 2003 Feb;21(1):15-20.
31 Development and characterization of a recombinant Madin-Darby canine kidney cell line that expresses rat multidrug resistance-associated protein 1 (rMRP1). AAPS PharmSci. 2004 Mar 9;6(1):E8.
32 Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma. Int J STD AIDS. 2017 Oct;28(12):1259-1262.
33 Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84.
34 Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
35 MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
36 Induction of CYP3A4 by vinblastine: role of the nuclear receptor NR1I2. Ann Pharmacother. 2010 Nov;44(11):1709-17.
37 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
38 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
39 Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J. 2005 Sep;272(18):4725-40.
40 MDR1 causes resistance to the antitumour drug miltefosine. Br J Cancer. 2001 May 18;84(10):1405-11. doi: 10.1054/bjoc.2001.1776.
41 MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005 Sep 20;116(5):824-9. doi: 10.1002/ijc.21013.
42 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
43 Microtubules are required for NF-kappaB nuclear translocation in neuroblastoma IMR-32 cells: modulation by zinc. J Neurochem. 2006 Oct;99(2):402-15. doi: 10.1111/j.1471-4159.2006.04005.x.
44 PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol. 2010 Sep;66(4):765-71. doi: 10.1007/s00280-009-1221-4. Epub 2009 Dec 30.
45 Protein kinase Cdelta-dependent induction of manganese superoxide dismutase gene expression by microtubule-active anticancer drugs. J Biol Chem. 1998 Dec 18;273(51):34639-45. doi: 10.1074/jbc.273.51.34639.
46 Cytoskeletal architecture differentially controls post-transcriptional processing of IL-6 and IL-8 mRNA in airway epithelial-like cells. Exp Cell Res. 2006 May 15;312(9):1496-506. doi: 10.1016/j.yexcr.2006.01.010. Epub 2006 Feb 24.
47 Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody. Cancer Immunol Immunother. 2003 Mar;52(3):185-93. doi: 10.1007/s00262-002-0357-4. Epub 2003 Feb 7.
48 Nocodazole-induced p53-dependent c-Jun N-terminal kinase activation reduces apoptosis in human colon carcinoma HCT116 cells. J Biol Chem. 2002 Nov 15;277(46):43648-58. doi: 10.1074/jbc.M203214200. Epub 2002 Sep 6.
49 Inhibition of drug-induced Fas ligand transcription and apoptosis by Bcl-XL. Mol Cell Biochem. 2001 Sep;225(1-):7-20. doi: 10.1023/a:1012203110027.
50 Zinc and the cytoskeleton in the neuronal modulation of transcription factor NFAT. J Cell Physiol. 2007 Jan;210(1):246-56. doi: 10.1002/jcp.20861.
51 Amyloid beta protein-related death-inducing protein induces G2/M arrest: Implications for neurodegeneration in Alzheimer's disease. J Neurosci Res. 2007 Aug 1;85(10):2262-71. doi: 10.1002/jnr.21351.
52 E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents. Cancer Res. 2006 Jul 15;66(14):7253-60. doi: 10.1158/0008-5472.CAN-05-3725.
53 CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways. BMC Cancer. 2006 Mar 18;6:75. doi: 10.1186/1471-2407-6-75.
54 Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia. Mol Cancer Ther. 2006 Aug;5(8):1986-94.
55 Targeted inhibition of Livin resensitizes renal cancer cells towards apoptosis. Cell Mol Life Sci. 2007 May;64(9):1137-44. doi: 10.1007/s00018-007-6510-7.
56 Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999 Apr 1;18(13):2241-51. doi: 10.1038/sj.onc.1202526.
57 c-myc antisense oligonucleotides sensitize human colorectal cancer cells to chemotherapeutic drugs. Tumour Biol. 2008;29(5):287-303. doi: 10.1159/000156706. Epub 2008 Sep 19.